Aromatase inhibitors (AI) are being evaluated as longterm adjuvant therapies and chemopreventives in breast cancer. However, there are concerns about bone mineral density loss in an estrogen-free environment. Unlike nonsteroidal AIs, the steroidal AI exemestane may exert beneficial effects on bone through its primary metabolite 17-hydroexemestane. We investigated 17-hydroexemestane and observed it bound estrogen receptor A (ERA) very weakly and androgen receptor (AR) strongly. Next, we evaluated 17-hydroexemestane in MCF-7 and T47D breast cancer cells and attributed dependency of its effects on ER or AR using the antiestrogen fulvestrant or the antiandrogen bicalutamide. 17-Hydroexemestane induced proliferation, stimulated cell cycle progression and regulated transcription at high sub-micromolar and micromolar concentrations through ER in both cell lines, but through AR at low nanomolar concentrations selectively in T47D cells. Responses of each cell type to high and low concentrations of the nonaromatizable synthetic androgen R1881 paralleled those of 17-hydroexemestane. 17-Hydroexemestane downregulated ERA protein levels at high concentrations in a cell type -specific manner similarly as 17B-estradiol, and increased AR protein accumulation at low concentrations in both cell types similarly as R1881. Computer docking indicated that the 17B-OH group of 17-hydroexemestane relative to the 17-keto group of exemestane contributed significantly more intermolecular interaction energy toward binding AR than ERA. Molecular modeling also indicated that 17-hydroexemestane interacted with ERA and AR through selective recognition motifs employed by 17B-estradiol and R1881, respectively. We conclude that 17-hydroexemestane exerts biological effects as an androgen. These results may have important implications for long-term maintenance of patients with AIs.
Introduction
The third-generation aromatase inhibitors (AI) anastrozole (Arimidex; refs. 1, 2), letrozole (Femara; refs. 3, 4) , and exemestane (Aromasin; refs. 5, 6) , by virtue of blocking extragonadal conversion of androgens to estrogens and giving rise to an estrogen-depleted environment, exhibit improved efficacy over tamoxifen in the adjuvant therapy of estrogen receptor (ER) -positive breast cancer in postmenopausal women (7) . Clinical trials evaluating these AIs showed a reduced incidence of contralateral primary breast cancer in the AI groups compared with tamoxifen (1 -6); hence, AIs are currently being evaluated as chemopreventives in ongoing studies (8) . AIs also exhibit reduced overall toxicity compared with tamoxifen (1 -6, 9) , but the toxicity profiles are different: tamoxifen is associated with increased incidences of thromboembolic events and endometrial cancer, whereas AIs are associated with decreased bone mineral density (BMD), coupled with an increased risk of bone fractures (10 -12) and severe musculoskeletal pain that limits patient compliance (13, 14) . Because the available third-generation AIs all exhibit similar efficacies, the selection of a specific AI for long-term adjuvant therapy of breast cancer and as a chemopreventive in healthy women at high risk for breast cancer will likely be determined by safety and tolerability profiles.
AIs fall into two classes, steroidal as represented by exemestane, which acts as a suicide inhibitor of aromatase, and nonsteroidal including anastrozole and letrozole, which reversibly block aromatase activity (7) . Possibly due to its steroid structure, exemestane may exhibit a unique pharmacology distinct from the nonsteroidal AIs. In two preclinical studies by Goss et al. (15, 16) , exemestane was given to female ovariectomized rats, an animal model of osteoporosis, and found to reduce bone resorption markers and increase BMD and bone strength, whereas lowering serum cholesterol and low-density lipoprotein levels compared with ovariectomized controls. One of these preclinical studies also evaluated the nonsteroidal AI letrozole, but in contrast, found no benefit of letrozole on bone or lipid profiles (16) . In a clinical study investigating the effects of 2 years of exemestane on bone compared with placebo without prior tamoxifen therapy in patients with surgically resected breast cancer at low risk for recurrence, exemestane did not enhance BMD loss in lumbar spine and only modestly enhanced BMD loss in the femoral neck compared with the placebo group (17) . Interestingly, in this study, exemestane promoted bone metabolism by increasing levels of both bone resorption and formation markers (17) . However, a clear-cut advantage of exemestane versus the nonsteroidal AIs on bone safety has not been shown in humans, possibly because all other clinical studies compared the AI to tamoxifen (9, 12, 18) or the AI to placebo with prior tamoxifen therapy (10, 11) . Drawing conclusions from these studies is difficult because tamoxifen preserves BMD, thereby protecting against fractures, and withdrawal of tamoxifen may have lasting effects on BMD (19) .
Maintenance of BMD in women is a known estrogenic effect (20) . However, androgen receptors (AR) are also expressed in multiple bone cell types (21, 22) , and studies show that androgens maintain BMD in ovariectomized rats (23, 24) and in women (21, 25 -27) . In ovariectomized rats, physiologic concentrations of androstenedione, a weak androgen and a substrate of aromatase, reduced loss of bone, and the antiandrogen bicalutamide abrogated this effect (23) , but anastrozole did not (23) . Therefore, the protective effect of androstenedione on maintenance of BMD was androgen mediated and not due to aromatization of androstenedione to estrogen. Furthermore, the nonaromatizable androgen 5a-dihydrotestosterone has been shown to stimulate bone growth in osteopenic ovariectomized rats (24) . In pre-and postmenopausal women, endogenous androgen levels correlate with BMD (25, 26) . Furthermore, a study comparing estrogen to a synthetic androgen in postmenopausal osteoporotic women showed that both steroids were equally effective in reducing bone resorption (27) . Also, a 2-year double-blind trial showed that estrogen plus a non-aromatizable androgen significantly improved BMD over estrogen alone in surgically menopausal women (28) . Therefore, exogenous androgens promote BMD maintenance in women when used alone (27) and in conjunction with estrogen (28) .
Although exemestane does not bind ER, it is structurally related to androstenedione and has weak affinity for AR (29, 30) . At high doses, exemestane exerts possible androgenic activity in vivo by inducing an increase in ventral prostate weight in immature castrated rats (29) . Recently, Miki et al. (22) showed in human osteoblast hFOB and osteosarcoma Saos-2 cells that exemestane promoted proliferation, which was partially blocked by the antiandrogen hydroxyflutamide, and increased alkaline phosphatase activity. However, metabolites of exemestane may be mediating these effects. Exemestane is given p.o. at 25 mg/day and rapidly absorbed, showing peak plasma levels within 2 to 4 h and a direct relationship between dosage and peak plasma levels after single (10 -200 mg) or repeated doses (0.5 -50 mg; refs. 30, 31) . Single-dose studies suggested that exemestane has a short elimination half-life, but multiple-dose studies show its terminal half-life to be about 24 h. Exemestane undergoes complex metabolism, and the primary metabolite in plasma has been identified as 17-hydroexemestane, which accumulates to a concentration of about 10% of its parent compound (30) . Taking the possible action of metabolites into consideration, Goss et al. (16) administered 17-hydroexemestane to ovariectomized rats and found that it produced the same bonesparing effects and favorable changes in circulating lipid levels as exemestane. Also, Miki et al. (22) stated that 17-hydroexemestane promoted proliferation of the osteoblast and osteosarcoma cells similar to exemestane, but the data were not shown, and the authors did not further explore 17-hydroexemestane activities. Additionally, Miki et al. (22) showed that the osteoblasts efficiently metabolized androstenedione to testosterone, which involves the reduction of the 17-keto group of androstenedione to a hydroxyl group. Similar metabolism would convert exemestane to 17-hydroexemestane, and thus, activities of exemestane in the osteoblasts may have been mediated by a metabolite of exemestane. Hence, a thorough investigation of exemestane and 17-hydroexemestane activities through ER and AR is warranted to provide evidence regarding whether exemestane could display a more favorable safety and toxicity profile than nonsteroidal AIs for long-term adjuvant use and as a chemopreventive of breast cancer in postmenopausal women. Therefore, we evaluated the pharmacologic actions of exemestane and its primary metabolite 17-hydroexemestane on ER-and AR-regulated activities in a range of cellular and molecular assays. First, we determined the relative binding affinity (RBA) of 17-hydroexemestane to ERa and AR. Next, using MCF-7 and T47D breast cancer cells, we examined the ability of 17-hydroexemestane to stimulate cell proliferation and cell cycle progression (Supplementary Material) 4 via ER and AR, to regulate ER-and AR-dependent transcription, and to modulate ERa and AR protein levels. Lastly, we investigated intermolecular interactions between 17-hydroexemestane and ERa and AR using molecular modeling.
Materials and Methods
Compounds and Cell Lines Exemestane and 17-hydroexemestane were provided by Pfizer. Fulvestrant (ICI 182,780, Faslodex) and bicalutamide (Casodex) were provided by Dr. Alan E. Wakeling and Dr. Barrington J.A. Furr (AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom), respectively. All other 4 Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/). compounds were obtained from Sigma-Aldrich, and cell culture reagents were from Invitrogen. All test agents were dissolved in ethanol and added to the medium at 1:1,000 (v/v). MCF-7/WS8 and T47D:A18 human mammary carcinoma cells, clonally selected from their parental counterparts for sensitivity to growth stimulation by E 2 (32) , were used in all experiments indicating MCF-7 and T47D cells. Cells were maintained in steroid-replete RPMI 1640, but 3 days before all experiments, were cultured in steroid-free media as previously described (32, 33) .
Competitive Hormone-Binding Assays Competitive hormone-binding assays were conducted using fluorescence polarization -based ERa and AR Competitor Assay kits (Invitrogen) as previously described (34) .
Cellular Proliferation Assays Cellular proliferation following 7 days in culture was determined by DNA mass per well in 12-well plates using the fluorescent DNA dye Hoechst 33258 as previously described (32) .
Reporter Gene Assays Reporter gene assays were conducted by transfecting cells with either an ERE(5x)-regulated (pERE(5x)TA-ffLuc; ref. 33) or ARE(5x)-regulated (pAR-Luc; Panomics) firefly luciferase expression plasmid and co-transfected with a basal TATA promoter-regulated (pTA-srLuc) Renilla luciferase expression plasmid as previously described (33) .
Quantitative Real-Time PCR Quantitative real-time PCR (qPCR) was used to determine AR and ribosomal large phosphoprotein subunit P0 (RLP0; 36B4) mRNA levels as previously described (35) .
Immunoblot Analyses Immunoblots, prepared as previously described (33), were probed with primary antibodies against AR (AR 441; Lab Vision), ERa (AER 611; Lab Vision), and h-actin (AC-15; Sigma-Aldrich).
Molecular Modeling and Virtual Docking Calculations
The three-dimensional conformations for E 2 , 17-hydroexemestane, exemestane, R1881, and dexamethasone were generated with Omega version 2.1 software (OpenEye Scientific Software). These compounds were docked using the following X-ray crystallographic structures: 1GWR (ERa co-complexed with E 2 , 2.4-Å resolution; ref. 36 ) and 1XQ3 (AR co-complexed with R1881, 2.25-Å resolution; ref. 37) . ERa and AR ligand-binding pockets were built using a ligand-centered box and the receptor-bound conformation of the respective ligand: E 2 (for 1GWR) and R1881 (for 1XQ3). The volume of the cavity differs for the two receptors: 648 Å 3 for 1GWR and 532 Å 3 for 1XQ3. All receptor and ligand bonds were kept rigid. The receptor structures were filled with water because ERa (38) and AR crystal structures (39) indicate that specific stable hydrogen bond (H-bond) networks form among particular water molecules, ligands, and amino acid side chains. Docking was done with FRED version 2.2 software (OpenEye) using a short refinement step for the ligands within the receptor and using the MMFF94 force field. The best 30 conformations for each compound were compared and ranked by FRED's Chemscore function. For each liganddocked receptor evaluated, the docked conformation with the lowest total intermolecular interaction energy (kJ/mol) was selected. To address whether water could be displaced by a compound during the process of binding, docking calculations were also done using receptors modeled with water removed as presented in Supplementary Table S1 4 and the differences between the methods in Supplementary  Table S2 . 4 Curve Fitting and Statistical Analyses All statistical tests, curve fitting, and determination of half-maximal inhibitory concentrations (IC 50 ) and halfmaximal effective concentrations (EC 50 ) were done using GraphPad Prism 4.03 (GraphPad Software). Significant differences were determined using one-way ANOVA with Bonferroni multiple comparison post-test.
Results
Experimentally Determined Binding of 17-Hydroexemestane and Exemestane to ERA and AR Structures of the compounds relevant to these studies, the steroidal AI parent compound exemestane, its primary metabolite 17-hydroexemestane, E 2 , and the synthetic non-aromatizable androgen R1881, are shown in Fig. 1A . Importantly, the only difference between parental exemestane and its metabolite 17-hydroexemestane is a hydroxyl group in the metabolite in place of a ketone in the parent compound at the 17h position, whereas both compounds share a 3-keto group. For steroidal estrogens, elimination or modification of the 17h-OH group reduces binding to ERa, but that of the 3-OH group is much more dramatic (40) . For steroidal androgens, the trend is reversed; elimination or modification of the 17h-OH group is more significant for AR binding than that of the 3-keto group (41) . The 3-keto group found in both exemestane and 17-hydroexemestane also favors binding to AR (41) .
We tested the binding of exemestane and 17-hydroexemestane to ERa and AR using fluorescence polarizationbased competitive hormone-binding assays ( Fig. 1B and C ; Table 1 ). For purposes of comparison, compound affinities were arbitrarily categorized with respect to their RBAs as strong (100 to z1), moderate (<1 to z0.1), weak (<0.1 to z0.01), very weak (<0.01 to detectable binding defined as 50% competition), and inactive (compound did not compete for at least 50% binding). À5 mol/L (RBA = 0.006), respectively, which categorized R1881 as a moderate and 17-hydroexemestane as a very weak ERa ligand. Neither exemestane nor dexamethasone significantly competed for binding to ERa. Regarding AR (Fig. 1C) 
Proliferation Responses to 17-Hydroexemestane and Exemestane
We examined the effects of exemestane and 17-hydroexemestane on 7 days of proliferation in ERa-and AR-positive MCF-7 and T47D mammary carcinoma cells (Fig. 2) . As expected, both cell lines were growth stimulated by E 2 , with growth EC 50 s of 1.7 Â 10 À12 mol/L E 2 for MCF-7 cells ( Fig. 2A ) and 7.1 Â 10 À12 mol/L E 2 for T47D cells (Fig. 2B) . These growth responses to E 2 were completely blocked by fulvestrant (all P values <0.001), validating the E 2 responsiveness via ER in these cell lines.
Both cell lines were also growth stimulated by R1881 ( Fig. 2A and B ) and 17-hydroexemestane ( Fig. 2C and D) , whereas exemestane did not exert any significant effect on proliferation (Fig. 2C and D) . Considering MCF-7 cells, R1881 exhibited a growth EC 50 of 2.4 Â 10 À8 mol/L ( Fig. 2A) , or approximately 4 orders of magnitude higher than that of E 2 . Similarly, 17-hydroexemestane exhibited a growth EC 50 of 2.7 Â 10 À6 mol/L in MCF-7 cells (Fig. 2C ) or approximately 6 orders of magnitude higher than that of E 2 . These growth responses to R1881 and 17-hydroexemestane in MCF-7 cells were completely blocked by cotreatment with fulvestrant ( Fig. 2A and B; both P values <0.001). Therefore, whereas R1881, a non-aromatizable synthetic androgen, stimulated growth of MCF-7 cells, it did so by acting through ER. Hence, at high concentrations, R1881 exerted estrogenic activity. Similarly, at high concentrations, 17-hydroexemestane also exerted estrogenic activity and stimulated growth of MCF-7 cells by acting through ER.
Interestingly, in T47D cells, the growth response to R1881 and 17-hydroexemestane followed an apparent bimodal pattern, which was different than in MCF-7 cells. In T47D cells, proliferative effects of high concentrations of R1881 (5 Â 10 À6 mol/L; Fig. 2B ) and 17-hydroexemestane (5 Â 10 À6 mol/L; Fig. 2D ) were only partially blocked by fulvestrant (both P values <0.001), down to the level of growth observed at nanomolar concentrations of these compounds. However, proliferative effects of lower concentrations of R1881 (10 À9 mol/L) and 17-hydroexemestane (10 À8 mol/L) were completely blocked by the antiandrogen bicalutamide (both P values <0.001). Based on these observed levels of inhibition by bicalutamide and fulvestrant, maximal concentrations at which R1881 and 17-hydroexemestane stimulated growth through ARdependent activities were 10 À7 and 10 À6 mol/L, respectively, and above these concentrations, R1881 and 17-hydroexemestane stimulated growth through ER-dependent activities. Using this information to define concentration ranges in which these compounds exert AR-mediated or ER-mediated effects in T47D cells, the growth EC 50 s via AR of R1881 and 17-hydroexemestane were 1.0 Â 10 À10 mol/L (Fig. 2B ) and 4.3 Â 10 À10 mol/L (Fig. 2D) , respectively. Similarly, the growth EC 50 s via ER of R1881 and 17-hydroexemestane in T47D cells were 3.1 Â 10 À7 mol/L (Fig. 2B ) and 1.5 Â 10 À6 mol/L (Fig. 2D) , respectively. Hence, in T47D cells, both R1881 and 17-hydroexemestane stimulated growth via AR at lower concentrations and via ER at higher concentrations. These results were consistent with the observed binding affinities of these compounds to ERa (Fig. 1B) and AR (Fig. 1C) .
Cell Cycle Progression Responses to 17-Hydroexemestane
As shown in Supplementary Fig. S1 , 4 17-hydroexemestane at 10 À8 mol/L acted through AR to stimulate S-phase entry in T47D cells by 1.9-fold (P < 0.001) but, at 5 Â 10 À6 mol/L, acted through ER to stimulate S-phase entry in MCF-7 cells by 2.2-fold (P < 0.001). Hence, 17-hydroexemestane effects on cell cycle progression were consistent with its effects on proliferation (Fig. 2) .
Regulation of ERA and AR Transcriptional Activities by 17-Hydroexemestane Next, we investigated the ability of 17-hydroexemestane to regulate ER and AR transcriptional activity by transfecting cells with an ERE(5x)-regulated or ARE(5x)-regulated dual-luciferase plasmid set, treating cells with test compounds, and measuring dual-luciferase activity 44 h after treatment (Fig. 3A -C) . E 2 at 10 À10 mol/L induced ERE(5x)-regulated transcription by 19.4-fold in MCF-7 cells ( Fig. 3A ; P < 0.001), and 11.3-fold in T47D cells ( Fig. 3B ; P < 0.001) compared with control-treated cells; this E 2 -induced transcriptional activity was blocked by fulvestrant (both P values <0.001), validating dependence on ER for ERE(5x)-regulated transcription. At high sub-micromolar and micromolar concentrations, R1881 stimulated ERE(5x)-regulated transcription in both cell lines, with maximal inductions of 22.7-fold at 5 Â 10 À6 mol/L in MCF-7 cells ( Fig. 3A ; P < 0.001), and 7.9-fold at 5 Â 10 À6 mol/L in T47D cells ( Fig. 3B ; P < 0.001) compared with control-treated cells. The ability of R1881 at 5 Â 10 À6 mol/L to induce ERE(5x)-regulated transcription was blocked by fulvestrant ( Fig. 3A and B; both P values <0.001), indicating that at high concentrations, R1881 acted as an estrogen. In a similar manner as R1881, 17-hydroexemestane stimulated ERE(5x)-regulated transcription in a concentration-dependent manner at sub-micromolar and micromolar concentrations ( Fig. 3A and B) . At 5 Â 10 À6 mol/L, 17-hydroexemestane maximally induced ERE(5x)-regulated transcription by 7.7-fold in MCF-7 cells ( Fig. 3A ; P < 0.001) and 3.3-fold in T47D cells ( Fig. 3B ; P < 0.001) compared with controltreated cells; this transcriptional activation was blocked by fulvestrant (both P values <0.001). Therefore, at high concentrations, 17-hydroexemestane acted as an estrogen and induced ER transcriptional activity.
In a similar manner, AR-dependent transcriptional activity was investigated. T47D cells showed a concentrationdependent induction of ARE(5x)-regulated transcription in response to R1881, with 10 À9 mol/L R1881 inducing transcription by 8.5-fold and 10 À6 mol/L R1881 maximally inducing transcription by 12.7-fold relative to controltreated cells ( Fig. 3C; both P values <0.001). Bicalutamide blocked 10
À9 mol/L R1881-mediated induction of ARE(5x)-regulated transcription ( Fig. 3C ; P < 0.001), confirming dependence on AR. MCF-7 cells failed to respond to 10 À6 mol/L R1881 with induction of ARE(5x)-regulated transcription (data not shown), although these cells express AR protein. This supports our prior results that T47D cells were growth stimulated by R1881 through an AR-dependent mechanism (Fig. 2B ), but that MCF-7 cells were not ( Fig. 2A) . As expected, 10 À6 mol/L E 2 failed to induce ARE(5x)-regulated transcription (Fig. 3C) . Next, 17-hydroexemestane was evaluated in T47D cells and, in a concentrationdependent manner, induced ARE(5x)-regulated transcription with maximal induction of 4.7-fold occurring at 5 Â 10 À6 mol/L relative to control treatment ( Fig. 3C ; P < 0.001). However, because high concentrations of 17-hydroexemestane were needed to induce this synthetic ARE(5x)-regulated promoter, we tested whether lower concentrations of 17-hydroexemestane could modulate endogenous AR mRNA expression, which is known to be negatively feedback regulated by its gene product (42) . Using real-time PCR, AR mRNA levels were determined in T47D cells following 24 h of treatment with test compounds (Fig. 3D ). R1881 at 10 À9 mol/L significantly down-regulated Table 1 . Compound affinity for ERA and AR determined experimentally using a competitive hormone-binding assay (Fig. 1B and C AR mRNA expression by 48% (P < 0.001), whereas 10 À9 mol/L E 2 did not (Fig. 3D) . Bicalutamide prevented R1881-mediated decrease in AR mRNA expression (Fig. 3D) , validating that AR mRNA levels were negatively feedback regulated. Similarly, a low 10 À8 mol/L concentration of 17-hydroexemestane led to a 41% decrease in AR mRNA levels (P < 0.01), with increased 17-hydroexemestane concentrations further decreasing AR mRNA expression (Fig. 3D) . Bicalutamide blocked 17-hydroexemestanemediated down-regulation of AR mRNA expression (P < 0.01), whereas fulvestrant did not (Fig. 3D) . Therefore, 17-hydroexemestane acted as an androgen via AR to feedback-regulate the expression of endogenous AR mRNA in T47D cells.
Modulation of AR and ERA Protein Levels by 17-Hydroexemestane
Androgens and estrogens modulate protein expression levels of their cognate receptors. R1881 stabilizes AR protein allowing its accumulation (43) , whereas E 2 promotes ERa degradation in a cell type -dependent manner (32) . Therefore, we investigated the effects of 17-hydroexemestane on AR and ERa protein levels by treating cells with test compounds for 24 h and analyzing receptor levels by immunoblotting. E 2 decreased ERa protein levels in MCF-7 (Fig. 4A ), but not T47D cells (Fig. 4B) , as we have previously shown (32) . As expected, fulvestrant promoted ERa protein degradation in both cell lines. E 2 did not significantly affect AR protein accumulation in MCF-7 cells ( Fig. 4A) , but did down-regulate AR protein levels in T47D cells (Fig. 4B) . Also, fulvestrant and E 2 plus fulvestrant treatments did not significantly affect AR protein levels in MCF-7 cells (Fig. 4A) , but did modestly up-regulate AR protein levels in T47D cells (Fig. 4B) . As expected, R1881 caused an increase in accumulation of AR protein in both cell lines (Fig. 4A and B) , likely by stabilizing the protein (43) . Next, we characterized the effects of low 10 À8 mol/L and high 5 Â 10 À6 mol/L concentrations of 17-hydroexemestane on ERa and AR expression. The high 5 Â 10 À6 mol/L concentration of 17-hydroexemestane led to decreased ERa protein levels in MCF-7 (Fig. 4A ), but not in T47D cells (Fig. 4B) (Fig. 4A and B) , indicating that 17-hydroexemestane acted as an androgen likely by stabilizing AR protein. Therefore, 17-hydroexemestane modulated ERa and AR protein accumulation as would an estrogen and an androgen, respectively.
Molecular Docking of 17-Hydroexemestane and Exemestane to ERA and AR To investigate the mechanism by which 17-hydroexemestane binds ERa as a very weak ligand and AR as a A -C, Under steroid-free conditions, cells were transiently transfected with pERE(5x)TA-ffLuc or pARE(5x)-Luc (firefly luciferase reporter plasmids) and the internal normalization control pTA-srLuc (Renilla luciferase reporter plasmid). Four hours after transfection, cells were treated as indicated and then again the following day. Cells were assayed 44 h after transfection for dual-luciferase activity. Data shown are the mean of triplicate determinations and associated SDs. 17-Hydroexemestane and R881 stimulated ERE(5x)-regulated transcription in MCF-7 and T47D cells and ARE(5x)-regulated transcriptional activity in T47D cells. D, AR mRNA levels in T47D cells as determined by real-time PCR. T47D cells were treated as indicated for 24 h. RNA was isolated and converted to cDNA. Continuous accumulation of PCR products was monitored using the double strand-specific DNA dye SYBR Green. Quantitative measurements of AR mRNA and the endogenous normalization control RLP0 mRNA were determined by comparison to a standard curve of known quantities of serially diluted AR or RLP0 PCR product. The data represent the mean and SDs of three independent samples, each of which was measured in triplicate. 17-Hydroexemestane and R881 down-regulated AR mRNA levels at nanomolar concentrations in an AR-dependent manner.
strong ligand, molecular models were constructed in silico. The trends in the computed intermolecular interaction energies matched the experimentally determined RBAs ( Table 1) . Superimposition of the docked and crystallographic structures of E 2 complexed with ERa (Fig. 5A) and of R1881 complexed with AR (Fig. 5B) showed that the docking models recapitulated the molecular recognition patterns of the crystal structures.
Considering ERa, the intermolecular interaction energies of R1881 and 17-hydroexemestane were less favorable than E 2 by 1.94 and 2.76 kJ/mol, respectively, due to decreased H-bond interactions and increased steric clash (Table 1) . Exemestane was much less favorable than E 2 by 4.57 kJ/mol (Table 1) . Hence, the 17h-OH group of 17-hydroexemestane compared with the 17-keto group of exemestane contributed À1.81 kJ/mol toward increased affinity for ERa. Interestingly, the docking calculations suggested that the higher affinity of 17-hydroexemestane over exemestane for ERa was not due to increased H-bonding mediated by the 17h-OH group, but rather increased lipophilic interactions (Table 1) due to a slight repositioning of the compound as a consequence of 17h-OH group. In the E 2 docked to ERa model, H-bonds between E 2 and Glu 353 , Arg 394 , and His 524 side chains were observed (Fig. 5A ). In the docked 17-hydroexemestane to ERa model (Fig. 5C ), the same Arg 394 and His 524 interactions were maintained, except that there was a loss of the Glu 353 interaction. The R1881 docked to ERa model is shown in Supplementary Fig. S2A . 4 Considering AR, the intermolecular interaction energy of 17-hydroexemestane was only 0.8 kJ/mol less favorable than R1881, whereas exemestane was significantly less favorable than R1881 by 6.27 kJ/mol (Table 1) . Docking of 17-hydroexemestane to AR, compared with the parent drug exemestane, indicated that 17-hydroexemestane exhibited improved lipophilic interactions by À2.11 kJ/mol, more favorable H-bonding interactions by À2.65 kJ/mol, and decreased steric clash by À1.08 kJ/mol. Hence, the 17h-OH group in 17-hydroexemestane compared with the 17-keto group in exemestane contributed À5.47 kJ/mol toward higher affinity for binding AR (Table 1 ). In the R1881 docked to AR model, H-bonds between R1881 and Asn 705 , Gln 711 and Arg 752 were observed (Fig. 5B) . The OH side chain of Thr 877 was in close proximity to both docked R1881 (Fig. 5B ) and 17-hydroexemestane (Fig. 5D ), but the angle was not favorable for H-bonding. Docking of 17-hydroexemestane to AR (Fig. 5D) Supplementary Fig. S2B . 4 
Discussion
We observed that 17-hydroexemestane, the primary metabolite of exemestane, bound to ERa as a very weak ligand and acted through ER at high sub-micromolar and micromolar concentrations to stimulate growth, promote cell cycle progression, induce ERE-regulated reporter gene expression, and down-modulate ERa protein levels in breast cancer cells. However, we also observed that 17-hydroexemestane bound to AR as a strong ligand and found in T47D cells that 17-hydroexemestane stimulated growth, induced cell cycle progression, down-modulated AR mRNA expression, and stabilized AR protein levels, with all of these effects occurring at low nanomolar concentrations and blocked by bicalutamide. Moreover, computer docking indicated that the 17h-OH group of 17-hydroexemestane versus the 17-keto group of exemestane contributed significantly more toward increasing affinity to AR than to ERa. Molecular modeling also indicated that 17h-OH group of 17-hydroexemestane interacted with AR through an important H-bond of Asn 705 , a conserved recognition motif employed by R1881. Therefore, we propose that the primary mechanism of action of exemestane in vivo is mediated by 17-hydroexemestane regulating AR activities.
The regulate AR-dependent activities. Furthermore, a subpopulation of patients may exist who metabolize exemestane at higher rates, leading to correspondingly higher circulating 17-hydroexemestane levels. For instance, one of three patients administered 800 mg of exemestane, the highest dose evaluated, achieved 17-hydroexemestane plasma levels approximately one-half the level of the parent compound (30) . Based on our results, we would predict that higher circulating levels of 17-hydroexemestane would associate with decreased rates of BMD loss and risk of bone fractures in postmenopausal women. We suggest that circulating levels of 17-hydroexemestane and exemestane should be determined in clinical trials and correlated to disease outcome and toxicity profiles such as BMD loss.
Although the clinical studies reported thus far were not designed to directly compare one AI versus another, comparisons in the rate of BMD loss from baseline to year 1, and from year 1 to 2 can be made. In the bone safety subprotocol of the IES (Intergroup Exemestane Study) trial, the rate of BMD loss was greatest within 6 months of switching from tamoxifen to exemestane at À2.7% in the lumbar spine and À1.4% in the hip, but thereafter, BMD loss progressively slowed in months 6 to 12 and again in months 12 to 24 to only À1.0% and À0.8% in the lumbar spine and hip, respectively (10), which is in the same range as would be expected for postmenopausal women in general. However, in the bone safety substudy of the MA.17 trial, patients administered letrozole experienced a relatively constant rate of BMD loss for 2 years: at 12 months, the rate of BMD loss from baseline was À3.3% and À1.43% in lumbar spine and hip, respectively, and from year 1 to year 2, À2.05% and À2.17% in lumbar spine and hip, respectively (11) . In the bone substudy of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial, the rate of BMD loss from baseline to year 1 was À2.2% in lumbar spine and À1.5% in hip and from year 1 to year 2, À1.8% in lumbar spine and À1.9% in hip (18) . Collectively, these results suggest that after the initial Figure 5 . Intermolecular interactions of ligands complexed with ERa and AR by computer docking. A, superposition of E 2 from the X-ray crystal structure (gray ) and modeled E 2 (yellow ) docked to ERa. B, superposition of R1881 from the crystal structure (gray ) and modeled R1881 (yellow ) docked to AR. C, modeled 17-hydroexemestane docked to ERa. D, modeled 17-hydroexemestane docked to AR. Cyan, red, and blue, hydrogen, oxygen, and nitrogen atoms, respectively. Green, carbon backbone of the protein. Hydrogens from the X-ray crystal conformations of E 2 (A) and R1881 (C) were omitted. H-bonds were shown to the modeled compound conformations only. Dashed lines, intermolecular H-bonds up to 3.5 Å; their length in angstroms is indicated.
12 months of AI therapy, exemestane may be associated with slower rates of BMD loss compared with nonsteroidal AIs. Furthermore, although not directly comparable, the fracture rate per 1,000 woman-years in the ATAC trial was 22.6 for anastrozole and 15.6 for tamoxifen (1) , whereas in the IES trial, the incidence rate per 1,000 woman-years for multiple fractures was 19.2 for exemestane and 15.1 for tamoxifen (10) . These results show that although both anastrozole and exemestane were associated with higher fracture rates than tamoxifen, they also suggest that exemestane may be associated with a lower fracture rate than anastrozole. Clinical trials now under way to directly compare the different AIs will hopefully provide clear results.
Androgens regulate growth of normal and neoplastic mammary cells in a cell type-specific manner, either by inhibiting or stimulating growth (44) . However, the mechanisms by which androgens via AR regulate breast cancer growth remain elusive. Female AR knock-out mice exhibit decreased ductal branching and terminal end buds in prepubertal animals and retarded lobuloalveolar development in adult animals (45) . Likewise, targeted disruption of AR in MCF-7 cells also leads to severe inhibition of proliferation (45) . Epidemiologic analyses indicate a positive correlation between androgen levels and the incidence of breast cancer; meta-analysis from nine prospective studies showed that a doubling in testosterone concentrations in postmenopausal women translated into an increased relative risk of 1.42 unadjusted and 1.32 adjusted for E 2 (46) . AR status in breast cancer associates with both positive and negative indicators and clinical outcome. AR expression has been found in 84% (47) to 91% (48) of clinical breast cancers, and associated with ER status, but has also been found in 49% of ER-negative tumors (49) . Patients with tumors that coexpress AR with ER and progesterone receptor have shown longer disease-free survival (DFS) than patients whose tumors were negative for all three receptors (48) , but AR protein levels have also served as an independent predictor of axillary metastases in multivariate analysis (47) Furthermore, AR expression has correlated with decreased histopathologic grade, greater age, and postmenopausal status, but also lymph node -positive status (50) . In AR-positive/ER-negative tumors, AR expression again associated with positive and negative indicators/outcome such as increased age, postmenopausal status, and longer DFS but also tumor grade, tumor size, and HER-2/neu overexpression (49) .
Patients who fail AI therapy, whether the AI was steroidal or nonsteroidal, likely harbor tumor cells that have been selected for growth in an estrogen-depleted environment and, hence, are not dependent on ER activity for survival. Not all androgens are metabolized by aromatase to estrogens; for instance, dihydrotestosterone cannot be converted to an estrogen by aromatase (44) . Thus, a possible mechanism for failure of AI therapy in the clinic is androgen-stimulated breast cancer growth, a largely unrecognized alternative mechanism. We observed cellular proliferation of T47D cells in response to R1881 and 17-hydroexemestane, and these effects were blocked by bicalutamide. Therefore, T47D cells contain a functional AR signaling pathway that promoted growth in the absence of estrogen. Because functional AR signaling could be etiologically involved in a subpopulation of clinical breast cancers, those patients who have AR-positive tumors and achieve high circulating levels of 17-hydroexemestane, yet whose disease progresses while on exemestane therapy, may respond to AR-based therapy such as the antiandrogen bicalutamide.
